Skip to main content
Bioinformation logoLink to Bioinformation
. 2024 Oct 31;20(10):1221–1232. doi: 10.6026/9732063002001221

Dengue infections in India: A meta-analysis

Dhirajkumar Mane 1,*, Satish V Kakade 2,*, Supriya S Patil 2,*
PMCID: PMC11904136  PMID: 40092891

Abstract

The escalating impact of dengue infection on health and mortality is a critical global issue. Therefore, it is of interest to assess the current trends of dengue infection in India. We searched through a wide range of internet databases to gather comprehensive studies on the incidence, prevalence, sero-prevalence, cost effectiveness and mortality rate of dengue infection in India from 2014 to 2023 (10 years) in a total of 127 studies. Analysis shows significant heterogeneity (diversity) in reported outcomes (p-values < 0.001). Thus, public health strategies should include early detection of dengue infection in our country.

Keywords: Dengue, dengue virus, burden of dengue, sero-prevalence, prevalence

Background:

Dengue is caused by an arbovirus of the Genus Flavivirus and Family Flaviviridae, is one of the most prevalent, fast-spreading vector-borne diseases impacting people [1]. As a result, research has shown that dengue disease may be clinically characterized as either mild dengue, dengue with or without warning signals, or severe dengue [1, 2]. According to a study, an estimated 105 million infections occur worldwide every year, only 51 million of which are symptomatic, making it a major public health issue [3]. Due to increasing worldwide travel and the geographical expansion of the Aedes vector mosquitoes, dengue virus are transmitted on all major continents, with new cases occurring and spreading to formerly non-endemic locations [4]. The primary dengue infection is presumed to provide permanent sterilizing immunity against homologous serotypes; however, exceptions exist in human and animal experimental investigations [5, 6]. Secondary infection (SC) with an un-encountered serotype often leads to classical dengue fever (fever) and is linked to a heightened risk of severe sequelae [7, 8]. This is a significant risk factor for the heightened severity of dengue fever via the antibody-dependent enhancement (ADE) pathway [9]. A second dengue fever occurring within two years after the first infection is likely to be an asymptomatic infection, as shown by the neutralizing antibody titer [10]. Therefore, it is of interest to assess dengue fever in India with the help of systematic review (SR) and meta-analysis (MA).

Material and Method:

Protocol development:

In the present manuscript, written according to the PRISMA checklist, [11] only the scientific evidence of dengue infection current Trent in India was investigated. This SR protocol was a priori registered in The International Prospective Register of SR (Registration No: CRD42024552341).

Search strategy, Databases & Selection criteria:

We have searched in electronic databases such as Cochrane Library, Medline, Web of Science (WoS), PubMed, Scopus & Google Scholar for publications published between January 2014 and December 2023. Appendix I: Search Strategy contains all of the search strategy's details. We have specifically used date/year as a filter to search three databases i.e. (PubMed, Scopus/Elsevier and Embase) from May 24-27, 2024. The Covidence application was used to screen abstracts.

Inclusion criteria:

[1] All studies conducted in India on this topic regardless of their design, purpose or population.

[2] Incidence

[3] Prevalence

[4] Number of cases

[5] Mortality

[6] Burden

[7] Complications

[8] Virus serotype details / seroprevalence

2 reviewers independently collected data from selected papers using a predefined data extraction form. Any discrepancies in it were resolved through consensus. The information that was extracted from studies includes year of publication, study setting, location, period, laboratory investigations, number of suspected patients tested & found positive, the age distribution of cases and details of dengue serotypes as shown in Table 1, Table 2, Table 3, Table 4, Table 5 to Table 6 (dataset I -VI).

Table 1. Dataset I-DG Proportion.

Sr. No. Reference No. Author Year of Publication Year of study Country Study Type (Hospital/Outbreak) Case Definition Referred Number of patients tested (Total) Number of people tested positive (Event)
1 12 Abhilash et al. 2016 2012-2013 India Hospital AFI 1258 386
2 13 Afreen et al. 2015 20112014 India Hospital AFI 604 416
3 14 Ahir et al. 2016 2014-2015 India Hospital Clinical Suspected Dengue 1146 148
4 15 Ahmad et al. 2016 2012-2013 India Hospital AFI 298 93
5 16 Ahmed et al. 2015 2010 India Hospital Clinical Suspected Dengue 4370 1700
6 17 Amudhan et al. 2015 2010-2013 India Hospital Clinical Suspected Dengue 4578 1185
7 18 Anand et al. 2016 2011 India Hospital WHO 112 94
8 19 Arora et al. 2021 2015 India Hospital Clinical Suspected Dengue 647 170
9 20 Badoni et al. 2023 2018-2019 India Hospital Clinical Suspected Dengue 279 222
10 21 Barde et al. 2014 2011-2012 India Hospital NVBDCP 138 21
11 22 Barde et al. 2015 2013 India Outbreak NVBDCP 648 321
12 23 Barde et al. 2015 2012 India Outbreak WHO 247 115
13 24 Barua et al. 2016 2014 India Hospital AFI 156 101
14 25 Bhattacharya et al. 2017 2013 India Hospital Clinical Suspected Dengue 218 168
15 26 Biswas et al. 2014 2012 India Outbreak Clinical Suspected Dengue 100 79
16 27 Chakravarti et al. 2014 2013 India Hospital Clinical Suspected Dengue 700 280
17 28 Changal et al. 2016 2015 India Hospital Clinical Suspected Dengue 225 114
18 29 Deshkar et al. 2017 2012-2016 India Hospital Clinical Suspected Dengue 15606 3822
19 30 Dhingra et al. 2020 Feb 2014-Oct 2015 India Hospital Clinical Suspected Dengue 255 216
20 31 Dinkar et al. 2020 2012-2017 India Hospital Clinical Suspected Dengue 900 461
21 32 Duthade et al. 2015 2014 India Hospital Clinical Suspected Dengue 872 233
22 33 Gopal et al. 2016 2013 India Hospital Clinical Suspected Dengue 50 25
23 34 Gopinath et al. 2023 2018-2022 India Hospital Clinical Suspected Dengue 1383 286
24 35 Gusani et al. 2017 2014 India Hospital NVBDCP 765 331
25 36 Henna et al. 2014 2010-2012 India Hospital Clinical Suspected Dengue 7836 2807
26 36 Henna et al. 2014 2012-2013 India Hospital Clinical Suspected Dengue 2228 527
27 37 Islam et al. 2016 2015 India Hospital AFI 62 18
28 38 Jindal et al. 2014 2011 India Hospital Clinical Suspected Dengue 1787 586
29 39 Joshua et al. 2016 2014-2015 India Hospital Clinical Suspected Dengue 4952 2442
30 40 Kartick et al. 2017 2014 India Outbreak Clinical Suspected Dengue 62 27
31 41 Kaup et al. 2014 2013-2014 India Hospital Clinical Suspected Dengue 278 62
32 42 Khan et al. 2014 2012 India Hospital Clinical Suspected Dengue 164 107
33 43 Lall et al. 2016 2015 India Hospital Clinical Suspected Dengue 3163 646
34 44 Laul et al. 2016 2015 India Hospital Clinical Suspected Dengue 192 115
35 45 Madan et al. 2018 Jun-Aug 2016 India Hospital Clinical Suspected Dengue 471 102
36 46 Mehta et al. 2014 2008-2011 India Hospital WHO 903 253
37 47 Mishra et al. 2015 2009-2012 India Hospital Clinical Suspected Dengue 433 136
38 48 Mistry et al. 2015 2013 India Hospital Clinical Suspected Dengue 4366 1802
39 49 Mital et al. 2016 2015 India Hospital AFI 90 61
40 50 Muruganandham et al. 2014 2013 India Outbreak WHO 23 13
41 51 Neeraja et al. 2014 2011-2013 India Hospital Clinical Suspected Dengue 175 109
42 52 Nikam et al. 2015 2014 India Hospital Clinical Suspected Dengue 1090 300
43 53 Nisarta et al. 2016 2015-2016 India Hospital Clinical Suspected Dengue 90 21
44 54 Nujum et al. 2014 2011 India Hospital WHO 851 174
45 55 Padhi et al. 2014 2010-2012 India Hospital WHO 5102 1074
46 56 Padmapriya et al. 2017 2009-2014 India Hospital Clinical Suspected Dengue 10099 1927
47 57 Palewar et al. 2023 2014-2020 India Hospital Clinical Suspected Dengue 6495 4689
48 58 Patankar et al. 2014 2012 India Hospital Clinical Suspected Dengue 4401 927
49 59 Patil et al. 2020 Jan 2019-Dec 2019 India Hospital WHO 640 220
50 60 Pothapregada et al. 2016 2012-2015 India Hospital WHO 398 261
51 61 Prakash et al. 2015 2011-2013 India Hospital Clinical Suspected Dengue 4019 886
52 62 Prakash et al. 2023 2021 India Hospital Clinical Suspected Dengue 250 85
53 63 Prudhivi et al. 2014 2013 India Hospital Clinical Suspected Dengue 1180 284
54 64 Ramachandran et al. 2016 2010 India Hospital Clinical Suspected Dengue 1666 930
55 65 Rao et al. 2016 2013 India Hospital Clinical Suspected Dengue 1980 745
56 66 Saravanan et al. 2017 2012 India Outbreak NVBDCP 600 260
57 67 Saswat et al. 2015 2013 India Hospital Clinical Suspected Dengue 204 73
58 68 Savargaonkar et al. 2018 2012-2015 India Hospital Clinical Suspected Dengue 5536 1536
59 69 Shabnum et al. 2017 2015 India Hospital Clinical Suspected Dengue 1054 456
60 70 Shah et al. 2019 2014-2016 India Hospital Clinical Suspected Dengue 819 125
61 71 Shaikh et al. 2015 2010 India Hospital Clinical Suspected Dengue 6554 3202
62 72 Sharma et al. 2016 2015 India Hospital WHO 60 16
63 73 Sharma et al. 2014 2013 India Hospital Clinical Suspected Dengue 659 141
64 74 Shobha et al. 2014 2013 India Outbreak WHO 68 13
65 75 Siddiqui et al. 2016 2015 India Hospital Clinical Suspected Dengue 7177 2358
66 76 Singh et al. 2014 2013 India Hospital AFI 1141 812
67 77 Singh et al. 2016 2015-2016 India Hospital Clinical Suspected Dengue 2709 1538
68 78 Singh et al. 2016 2015 India Hospital WHO 1100 400
69 79 Singh et al. 2023 2022 India Outbreak WHO 63280 2060
70 80 Singla et al. 2015 2011-2012 India Hospital AFI 300 22
71 81 Somasundaram et al. 2019 Jun 2017-Nov 2017 India Hospital Clinical Suspected Dengue 325 232
72 82 Sushi et al. 2014 2011 India Hospital AFI 100 8
73 83 Tazeen et al. 2017 2014 India Hospital Clinical Suspected Dengue 60 48
74 84 Vakrani et al. 2017 2013-2015 India Hospital WHO 139 101
75 85 Venkatasubramani et al. 2015 2010-2012 India Hospital Clinical Suspected Dengue 331 49
76 87 Yogeesha et al. 2014 2012 India Hospital Clinical Suspected Dengue 200 80

Table 2. Data set II-DG Age Distribution.

Sr. No. Reference No. Author Year of Publication Year of study Study. Type Avg./Median Age
1 16 Ahmed et al. 2015 2010 Hospital 25
2 89 Athira et al. 2018 2015-2017 Hospital 7.6
3 22 Barde et al. 2015 2012 Outbreak 33
4 23 Barde et al. 2015 2013 Outbreak 35
5 29 Deshkar et al. 2017 2012-2016 Hospital 14
6 32 Duthade et al. 2015 2014 Hospital 19
7 35 Gusani et al. 2017 2014 Hospital 24
8 89 Jain et al. 2017 Aug-Nov 2015 Hospital 30.9
9 90 John et al. 2019 2014-2018 Hospital 31.3
10 41 Kaup et al. 2014 2013-2014 Hospital 26
11 91 Kumar et al. 2018 Jan 2013-June 2014 Hospital 7.8
12 48 Mishra et al. 2015 2009-2012 Hospital 7
13 92 Mishra et al. 2018 2017 Hospital 33
14 49 Mistry et al. 2015 2013 Hospital 22
15 56 Padhi et al. 2014 2010-2012 Hospital 23
16 58 Palewar et al. 2023 2014-2020 Hospital 25
17 59 Patankar et al. 2014 2012 Hospital 23
18 60 Patil et al. 2020 Jan 2019-Dec 2019 Hospital 35.3
19 93 Pereira et al. 2018 Not Mentioned Hospital 32.41
20 64 Prudhivi et al. 2014 2013 Hospital 32
21 66 Rao et al. 2016 2013 Hospital 17
22 94 Ravikumar et al. 2021 Aug-Dec 2020 Hospital 8
23 67 Saravanan et al. 2016 2012 Outbreak 33
24 70 Shabnum et al. 2017 2015 Hospital 26
25 95 Sharma et al. 2014 2013 Hospital 16
26 83 Sushi et al. 2014 2011 Hospital 21
27 96 Swain et al. 2019 2010-2016 Hospital 31.6
28 88 Yogeesha et al. 2014 2012 Hospital 35
29 97 Esther et al. 2023 2012-2017 Hospital 32

Table 3. Dataset III-DG Fever (FV) and DG Severity (SV).

Sr. No. Reference No. Author Year of Publication Year of study WHO Case Definition Reference Dengue Positives DF Severe
1 12 Abhilash et al. 2016 2012-2013 WHO 1997 386 329 57
2 16 Ahmed et al. 2015 2010 WHO 1997 1700 1525 175
3 19 Arora et al. 2021 2015 WHO 2009 170 106 34
4 89 Athira et al. 2018 2015-2017 WHO 2009 34 31 11
5 28 Changal et al. 2016 2015 WHO 1997 114 84 30
6 98 Chatterjee et al. 2014 2012 WHO 1997 180 128 52
7 99 Chhotala et al. 2016 2014-2015 WHO 1997 100 94 6
8 100 Deme et al. 2021 August 2018-October 2019 WHO 2012 200 200 116
9 29 Deshkar et al. 2017 2012-2016 WHO 1997 3822 3341 481
10 101 Deshmukh et al. 2014 2012-2014 WHO 1997 247 173 74
11 30 Dhingra et al. 2020 Feb 2014-Oct 2015 WHO 2013 216 94 33
12 90 John et al. 2019 April 2014-October 2018 WHO 2012 369 198 171
13 102 Kumar et al. 2017 2015-2016 WHO 1997 159 69
14 91 Kumar et al. 2018 Jan 2013-June 2014 WHO 2012 40 20 20
15 44 Laul et al. 2016 2015 WHO 1997 306 119 56
16 103 Meena et al. 2016 2014 WHO 1997 115 89 26
17 104 Mishra et al. 2016 2013-2015 WHO 2007 100 84 16
18 105 Misra et al. 2015 2003-2014 WHO 1997 97 84 13
19 55 Padhi et al. 2014 2010-2012 WHO 1997 116 82 34
20 93 Pereira et al. 2018 Not Mentioned WHO 2009 1074 1048 26
21 106 Pothapregada et al. 2015 2012-2014 WHO 2007 550 547 101
22 107 Rathod et al. 2018 2013-2015 WHO 2009 254 159 95
23 94 Ravikumar et al. 2021 Aug-Dec 2020 WHO 2009 100 100 11
24 108 Sahana et al. 2015 2012-2013 WHO 2007 44 43 30
25 73 Sharma et al. 2016 2015 WHO 1997 81 61 20
26 109 Sil et al. 2016 2015-2016 WHO 1997 16 5 11
27 78 Singh et al. 2016 2015 WHO 1997 71 62 9
28 110 Singh et al. 2022 Sept-Dec 2019 WHO 1997 400 260 140
29 81 Somasundaram et al. 2019 Jun 2017-Nov 2017 WHO 2012 1349 459 34
30 111 Srividhya et al. 2017 2013 WHO 1997 232 232 38
31 84 Vakrani et al. 2017 2013-2015 WHO 1997 140 70 70

Table 4. Dataset IV.

Sr. No. Reference No. Author Year of Publication Year study Total Positive for Dengue No. of Mortality
1 12 Abhilash et al. 2016 2012-2013 386 9
2 112 Acharya et al. 2018 2017-2018 364 14
3 15 Ahmad et al. 2016 2012-2013 93 4
4 16 Ahmed et al. 2015 2010 1700 1
5 21 Barde et al. 2014 2011-2012 21 0
6 22 Barde et al. 2015 2012 321 5
7 24 Barua et al. 2016 2014 101 1
8 113 Bhalla et al. 2014 2011 299 2
9 25 Bhattacharya et al. 2017 2013 168 0
10 98 Chatterjee et al. 2014 2012 180 7
11 99 Chhotala et al. 2016 2014-2015 100 4
12 29 Deshkar et al. 2017 2012-2016 3822 40
13 101 Deshmukh et al. 2014 2012-2014 247 11
14 114 Deshwal et al. 2015 2013 515 4
15 30 Dhingra et al. 2020 Feb 2014-Oct 2015 216 13
16 32 Duthade et al. 2015 2014 233 5
17 90 Jain et al. 2017 2015 369 19
18 115 Krishnamoorthy et al. 2017 2013 1308 23
19 105 Mishra et al. 2016 2013-2015 97 1
20 116 Nagaram et al. 2017 2015-2016 174 9
21 51 Neeraja et al. 2014 2011-2013 109 9
22 117 Nimmagadda et al. 2014 2010-2012 150 3
23 118 Padyana et al. 2019 2015 1170 20
24 119 Pai Jakribettu et al. 2015 2013-2014 60 2
25 106 Pothapregada et al. 2015 2012-2014 254 6
26 106 Pothapregada et al. 2015 2012-2014 261 6
27 62 Prakash P 2023 2021 85 2
28 65 Rao et al. 2016 2013 745 0
29 108 Sahana et al. 2015 2012-2013 81 2
30 120 Sahu et al. 2014 2011-2013 486 5
31 66 Saravanan et al. 2016 2012 260 7
32 121 Saroch et al. 2017 2015 172 16
33 72 Sharma et al. 2016 2015-2016 200 0
34 73 Sharma et al. 2016 2015-2016 107 0
35 95 Sharma et al. 2014 2013 141 0
36 76 Singh et al. 2014 2013 812 12
37 79 Singh et al. 2023 Sept-Dec 2019 1349 6
38 122 Singhal et al. 2020 2017 575 15
39 111 Srividya et al. 2017 2013 140 1
40 84 Vakrani et al. 2017 2013-2015 101 0

Table 5. Dataset V.

Sr. No. Reference No. Author Year of Publication Year of study Total Tested Primary (PM) Secondary (SC)
1 22 Barde et al. 2015 2012 115 111 4
2 28 Changal et al. 2016 2015 114 38 76
3 33 Gopal et al. 2016 2013 25 13 12
4 41 Kaup et al. 2014 2013-2014 62 52 10
5 42 Khan et al. 2014 2012 87 82 5
6 104 Mishra et al. 2016 2013-2015 94 83 11
8 51 Neeraja et al. 2014 2011-2013 109 87 22
9 52 Nikam et al. 2015 2014 300 224 76
10 56 Padmapriya et al. 2017 2009-2014 1752 1124 628
11 65 Rao et al. 2016 2013 22 21 1
12 123 Rashmi et al. 2015 2014 97 93 4
13 114 Shabnum et al. 2017 2015 456 442 14
14 75 Siddiqui et al. 2016 2015 76 24 52
15 84 Vikram et al. 2016 2013 22 8 14

Table 6. Dataset VI.

Sr. No. Reference No. Author Year of Publication Year study Total Tested Tested as Seropositive
1 125 Alagarasu et al. 2023 2009-2019 2451 1963
2 20 Badoni et al. 2023 2018-2019 279 143
3 126 Garg et al. 2017 2011-2012 2558 1525
4 127 Lakshmi et al. 2022 2016-2019 5147 1314
5 124 Mishra et al. 2018 2017 1434 1163
6 128 Murhekar et al. 2019 2017-2018 12300 5338
7 129 Oruganti et al. 2014 Not mentioned 200 179
8 59 Patil et al. 2020 Jan 2019-Dec 2020 640 398
9 130 Rodríguez-Barraquer et al. 2015 2011 800 744
10 131 Vikram et al. 2016 2013 1899 542

Data extraction & Review synthesis:

3 reviewers carried out the initial screening. The collected literature was first searched to remove duplicates before being entered into Rayyan software [132]. After that, the titles and abstracts were screened. In 2nd screening phase, 3 reviewers evaluated the selected papers based on their compliance with the eligibility standards. While the 2, independently shortlisted studies that met the design, participant and result requirements. Disagreements were resolved by discussion and, if necessary, the involvement of a 3rd reviewer. Using a pre-designed data extraction form in Microsoft Excel, 3 reviewers independently gathered details from the selected research. Initially, the search results were imported into Mendeley software (Version 1.19.6) where duplicate records were removed.

The outcome measures were:

[1] The prevalence of laboratory-confirmed dengue infection among clinically suspected patients in the research area, as reported in hospital/laboratory or community-based investigations during outbreaks.

[2] Seroprevalence of dengue in the study population dengue fever conditions, dengue severity and Mortality rate among dengue patients those were confirmed in labs.

[3] Primary and secondary infections present.

[4] Cost of illness/burden which included reported direct and indirect costs associated with dengue hospitalization.

[5] The non-structural protein-1 (NS1) antigen, immunoglobulin M (IgM) antibodies against dengue virus, haem-agglutination inhibition (HI) antibodies against dengue virus, RT-PCR positivity, or virus isolation was used to diagnose acute dengue infection in the clinically suspected patients. The measurement of IgG or neutralizing antibodies against the dengue virus was used to determine the seroprevalence of dengue.

Quality/Risk of bias assessment:

We utilized a modified version of the Joanna Briggs Institute (JBI) appraisal checklist for assessing prevalence data [133], along with key components from the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist [134] to gauge potential bias. Our primary criteria for bias assessment included outcome variables, laboratory testing procedures and participant selection strategies (refer to Supplementary file S2 Appendix). 2nd reviewers independently evaluated bias risk, resolving any disagreements through discussion. In cases of unresolved disputes, the perspective of a 3rd reviewer was sought and any disagreements were resolved. When needed, the viewpoint of the 3rd reviewer was sought.

Statistical analysis:

Using the single user licenced version of STATA 18.5 StataCorp LLC, Texas, USA, software and R-Studio analysis was carried out. The proportions from the combined data were shown along with their 95% confidence intervals (CI). Heterogeneity was assessed using an I2-test, where values below 25% indicated mild heterogeneity, values between 25 and 75% indicated moderate heterogeneity and values over 75% indicated significant heterogeneity [15, 16]. Based on the inverse variance approach for weighting, the Der-Simonian-Laird method for a random-effects model was used to compute the total pooled prevalence. Both the pooled estimates for the general and subgroup analyses and the study-specific estimates for each participant were shown using forest plots. To further demonstrate publication bias, a funnel plot was made.

Results:

Initially, we searched 6582 published articles in various electronic databases such as PubMed-2281, Ovid/Medline-47, Web of Science-4037 and Google Scholar-217 published. This was later on narrowed down to 999 unique articles after duplicate removal over the last 10 years. Following titles and abstracts screening, 613 articles were excluded, leaving 386 articles for full-text evaluation. This resulted in 127 studies being selected for analysis [17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139-140] as shown in (Figure 1 see PDF).

Prevalence/proportion of laboratory dg cases & outbreak:

The clinically suspected patients are provided by 78 out of the 127 published studies included in this synthesis. This comprised 8 studies reporting outbreak investigations and 71 studies conducted in hospital or laboratory settings. A proportion of the studies that the hospital validated were conducted at the time; that the affected areas were going through an outbreak. The data of laboratory-confirmed cases by month were supplied by 32 research (40.5%) out of the 79 studies that reported a proportion of dengue cases; the majority of these studies (n = 53, 67%) indicated increased dengue positivity throughout the rainy seasons, particularly from July to October. The majority of the forty-seven investigations identified acute dengue infection using a single test, as follows: detection of the NS1 antigen = 1, virus isolation = 1, RT-PCR (Real-Time Reverse Transcription - Polymerase Chain) = 7, haem-agglutination inhibition antibodies = 2 and IgM antibodies = 36. The other studies employed multiple tests.

Case definitions used:

While discussed about case studies their; we took assistance of WHO (World Health Organizations), NVBDCP (National Center for Vector Borne Diseases Control) & AFI (Acute Febrile Illness) case definitions. Out of 79 studies during hospital settings majority n=53 were clinical suspected dengue followed by n=13 WHO case definition, n=9 AFI case definition and the remaining studies n=4 were used NVBDCP case definitions respectively. Both hospital confirmed dengue study and showed similarly, among 71 hospital confirmed dengue cases n=51 were clinical suspected dengue followed by n=9 WHO case definition, n=9 AFI case definition and the remaining studies n=2 were used NVBDCP case definitions respectively. Among the reported outbreaks, investigators used n=4 WHO case definition, n=2 AFI case definition and the remaining studies n=2 were used NVBDCP case definitions respectively.

Dengue proportion in India:

Based on testing of 206783 clinically suspected individuals from 78 studies, the overall estimate of the prevalence of laboratory-confirmed dengue infection in the random effects model was 39.4% (95% CI: 35.6%-44.67%) as shown in (Figure 2 see PDF). The heterogeneity was assessed by Hedge g statistics. The heterogeneity overcomes by using random effect model as shown in (Figure 3 see PDF). The publication biased(PB) was assessed by using funnel plot, some asymmetry observed because individual study had different proportion and this was directly impacts on shifting the points on funnel to outside but the both the side almost normality hence in our study there was no publication bias was reporting as shown in. The prevalence reported by the 79 studies showed significant heterogeneity (LRT p<0.001). In comparison to hospital-based surveillance (HBS) studies (40%, 95% CI: 35-44), the prevalence of laboratory-confirmed dengue infection was nearly identical in studies reporting outbreaks (OB) or hospital-based surveillance studies during outbreaks (39%, 95% CI: 34-44).

Age distribution:

Data was available for 30 out of 127 studies on laboratoryconfirmed DG cases. The overall average age of confirmed DG patients in this study was 24.47 years; with a standard deviation of 9.22 years with age range was 7 to 36 years as shown in (Figure 4 - see PDF).

Dg-FV & Dg-S proportion:

31 studies provided information on dengue fever, while 32 studies provided information on dengue symptoms. The majority of the research (n = 19, 59.38%) utilized the WHO 1997 classification, while the remaining studies (n = 3, 9.38%) employed the WHO 2007 classification. Additionally, for dengue fever condition and severity, (n = 6, 18.75%) used the WHO 2009 classification, whereas 4 studies (12.5%) used the WHO 2012 classification. It was reported that between 31% and 100% of laboratory-confirmed patients had dengue fever. According to the random effect model, 75% (95% CI: 67-82) of laboratory-confirmed studies exhibited dengue fever overall. The Hedges g-Method (HD-M) was used to estimate the random effect model, indicating no heterogeneity as shown in (Figure 5 see PDF). Bias in publications observed and depicted that higher prevalence publications were more side. On the other hand, among patients with laboratory-confirmed, the reported percentage of dengue symptoms cases varied from 2% to 69%. In the random effect model (REM), the total percentage of dengue symptoms across laboratory-confirmed studies was 25% (95% CI: 19-31). The data on dengue symptoms showed no evidence of heterogeneity as shown in (Figure 6 see PDF).

DG Mortality (MT) in India:

In the provided research, 48 provided information on MT rate of DG, It was reported that between 0% and 9% of LB-CN patients had DG-FV. According to the REM, 1% (95% CI: 1-2) of LB-CN studies exhibited DG-FV overall. The HD-M was used to estimate the REM, indicating no HTG. Bias in publications observed and depicted that higher prevalence publications was more side, The removal of the study with greatest weight in each LB-CN test of DG disease did not change the results.

Pm-if & SC among dg cases in India:

A comprehensive analysis of 15 studies [31, 37, 48, 59-60, 71, 78, 81- 82, 89, 104- 105, 115, 124] enabled the categorization of LB-CN-DG-IF into PM and SC. The prevalence of initial DG-IF varied widely ranges from 32% to 97% across the studies. Overall, PM-DG-IF accounted for 77% of LB-CN cases (95% CI: 65-87). Meanwhile, SC-DG-IF occurred in 23% of LB-CN cases (95% CI: 13-35), with a range of 3% to 68% across the studies.

PB-BA & sensitivity statistics (SS-ST):

There was no indication of publication bias in the dengue prevalence estimates from hospital-based studies with LB-CN cases, outbreaks & SP according to analysis utilizing funnel plots and the HD approach. The estimates of dengue severity and fatality did, however, reveal a substantial publication BA, with publications demonstrating higher prevalence being more likely to be published. However, sensitivity analysis showed that the pooled percentages of research results held steady, suggesting the estimates' resilience. The removal of the study with greatest weight in each dengue cases LB-CN did not change the results.

Discussion:

The analysis primarily drew on data from HB and laboratorybased surveillance studies, as well as reports from investigations into dengue outbreaks. There have been more than 10 million reported cases of dengue along with over 5,000 dengue-related deaths across 80 countries. The Pan American Health Organization (PAHO) region has reported the majority of cases, with over nine million cases. Within the PAHO region, Brazil has reported the highest number of cases (over eight million), followed by Argentina, Paraguay, Peru and Colombia. In Europe, imported cases from endemic areas have been reported in Germany, Italy and France, but no locally acquired cases have been reported.

Dengue circulation has also been reported in the Southeast Asia and Western Pacific regions, as well as in Africa. It concentrated on their operations, implementation and structure. The WHO had set aggressive goals to cut dengue-related mortality by 50% and morbidity by 25% along with burden by 2020 [135-136]. A recent study in Brazil found a significant disparity in the infection rates between wealthy and disadvantaged youth. Specifically, the study revealed that 60% of young people from disadvantaged backgrounds were infected, which is three times the rate of their wealthier peers and our study also found similar kind of results where average age was 24.4 years [137]. Overall, 127 studies with a total of 3Lacs population were covered for study of dengue disease in our country. Viral assays are used in laboratories to confirm dengue infection (RNA detection by RTPCR, NS1 antigen detection by ELISA) [138]. The overall prevalence of dengue disease in our India based on testing of 206783 clinically suspected individuals from 79 studies, the overall estimate of the prevalence of laboratory-confirmed - dengue infection in the random effect model was 39.4% (95% CI: 35.6%-44.67%) According to a study, the overall prevalence of dengue in country like India based on testing 206783 clinically suspected individuals from 79 different studies was 39.4% [139].

There are also research gaps in India's understanding of dengue epidemiology and the fact that different types of the dengue virus are still being spread. These factors show that dengue is still a major public health issue in India. The high percentage of dengue-positive cases, severity and case mortality in India are all indicators that dengue continues to be a significant public health concern in the country. As a consequence of this, it is required to undertake community-based cohort studies that are wellstructured and cover a variety of geographical locations of the country in order to offer reliable estimates of the age-specific incidence of dengue fever in India [140].

Conclusion:

DG-FV remains a pressing public health issue in India, as indicated by its high incidence, severity and mortality rates, as well as the circulation of multiple virus serotypes. To better comprehend the epidemic, we suggest conducting in-depth research, including community-based studies across various regions to determine age-specific incidence rates. Alternatively, a nationwide survey could be undertaken to determine age-specific seroprevalence rates, which also includes targeted studies in different geographic areas in India.

Limitation:

[1] We have restricted our search to quantitative sides which might be neglected towards qualitative enrichment of variables

[2] We considered peer-reviewed journals database from certain articles, which lead to exclusion of government registries data as a grey literature that could provide other aspects of the picture too.

Future research:

We should implement active surveillance systems, scaling up vector control measures, enhance more public awareness & education and finally, strengthen the prevention strategies.

Edited by Neelam Goyal & Shruti Dabi

Citation: Mane et al. Bioinformation 20(11):1221-1232(2024)

Declaration on Publication Ethics: The author's state that they adhere with COPE guidelines on publishing ethics as described elsewhere at https://publicationethics.org/. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

Declaration on official E-mail: The corresponding author declares that official e-mail from their institution is not available for all authors.

License statement: This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License

Comments from readers: Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article without open access charges. Comments should be concise, coherent and critical in less than 1000 words.

Bioinformation Impact Factor:Impact Factor (Clarivate Inc 2023 release) for BIOINFORMATION is 1.9 with 2,198 citations from 2020 to 2022 taken for IF calculations.

Disclaimer:The views and opinions expressed are those of the author(s) and do not reflect the views or opinions of Bioinformation and (or) its publisher Biomedical Informatics. Biomedical Informatics remains neutral and allows authors to specify their address and affiliation details including territory where required. Bioinformation provides a platform for scholarly communication of data and information to create knowledge in the Biological/Biomedical domain.

References


Articles from Bioinformation are provided here courtesy of Biomedical Informatics Publishing Group

RESOURCES